24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
CytoReason
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
10:39
Intel’s decision to keep NEX signals stability for Israel’s 350 networking staff
10:29
Intel VP: “We had 11 or 12 layers of management... now it’s 5 or 6”
21:48
From textile recycling to autonomous vessels: The vision behind the Dream Team startups
20:25
ELNET: German business leaders “are looking with admiration and respect towards the Startup Nation”
More stories
Buzz
Most popular
Daily
Weekly
1
Inside the mind of a Nobel physicist: John Martinis on the future of quantum computing
2
Check Point raises $1.75 billion, potentially eyeing AI expansion
3
Hapag-Lloyd eyes ZIM acquisition, workers push back
4
Sequoia’s Shaun Maguire says Israel risks losing “a war it can’t see”
5
Cybereason founders' 7AI raises record $130 million Series A in breakneck rise
More news
CytoReason
4 stories about CytoReason
CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models
17.07.24
|
Meir Orbach
The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform
20.09.22
|
Meir Orbach
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
CytoReason enters Japanese market with SPI partnership
30.09.21
|
James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason
10.01.19
|
Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars